FOCAL ONSET SEIZURES
Clinical trials for FOCAL ONSET SEIZURES explained in plain language.
Never miss a new study
Get alerted when new FOCAL ONSET SEIZURES trials appear
Sign up with your email to follow new studies for FOCAL ONSET SEIZURES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug SPN-817 aims to tame Hard-to-Control seizures
Disease control Recruiting nowThis study tests whether SPN-817 can reduce seizure frequency in adults with focal onset seizures that don't respond well to current medications. About 216 participants will receive either SPN-817 or a placebo, and researchers will track seizure changes over 14 weeks. The goal is…
Matched conditions: FOCAL ONSET SEIZURES
Phase: PHASE2 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill could tame focal seizures when other drugs fail
Disease control Recruiting nowThis Phase 3 trial tests whether XEN1101 (azetukalner) can safely reduce seizure frequency in people with focal-onset seizures. About 360 adults whose seizures aren't controlled by current medications will receive either XEN1101 or a placebo added to their existing treatment. The…
Matched conditions: FOCAL ONSET SEIZURES
Phase: PHASE3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New epilepsy drug SPN-817 put to the test in Year-Long safety study
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of a drug called SPN-817 in adults with focal onset seizures (a type of epilepsy). About 100 people who completed a previous SPN-817 study will take the drug for one year. Researchers will track side effects and measure chan…
Matched conditions: FOCAL ONSET SEIZURES
Phase: PHASE2 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC